Abivertinib Maleate Anhydrous

Drug Overview

Abivertinib maleate anhydrous is a highly advanced, modern medicine designed to fight specific types of cancer and severe immune reactions. It belongs to a group of medicines known as Targeted Therapies or “Smart Drugs.” Unlike older treatments that affect the whole body, this medicine is designed to seek out and block only the specific broken parts of a cell that cause disease.

• Generic Name: Abivertinib maleate anhydrous (also known simply as abivertinib or AC0010)
• US Brand Names: Fujovee™ (Investigational name)
• Drug Class: Third-Generation EGFR Tyrosine Kinase Inhibitor (TKI) / BTK Inhibitor / Targeted Therapy
• Route of Administration: Oral (taken by mouth as a pill or capsule)
• FDA Approval Status: Investigational. Currently, abivertinib is heavily studied in advanced Phase 2 and Phase 3 clinical trials. While it has received special “Fast Track” designations from the FDA for certain uses, it is not yet fully approved for standard, everyday prescription in the United States.

What Is It and How Does It Work? (Mechanism of Action)

Abivertinib is a Targeted Therapy that acts as a double-agent. It works at the molecular level by blocking two different protein “switches” in the body: EGFR and BTK.

• Blocking the Cancer Engine (EGFR): All cells have a protein on their surface called the Epidermal Growth Factor Receptor (EGFR). This protein tells the cell when to grow and divide. In some lung cancers, the DNA mutates (specifically, a mutation named T790M). This mutation acts like a gas pedal that is stuck to the floor, causing the cancer cells to multiply rapidly. Abivertinib binds permanently to this specific mutated EGFR protein and turns it off. Because it is a “third-generation” drug, it ignores the healthy, normal EGFR proteins, which helps prevent severe side effects on the skin and stomach.
• Calming the Immune System (BTK): Abivertinib also blocks a second protein called Bruton’s Tyrosine Kinase (BTK). BTK is a key messenger in the immune system. By blocking BTK, abivertinib can stop certain cancer cells (like in prostate cancer or lymphoma) from getting the fuel they need to grow. Furthermore, blocking BTK calms down the immune system, preventing it from overreacting and causing dangerous inflammation (like the lung damage seen in severe viral infections).

FDA Approved Clinical Indications

Because abivertinib is an investigational drug, it does not have standard FDA approvals for the general public yet. However, it is authorized for the following specific uses within clinical trials:

Oncological Uses (Investigational)

• Non-Small Cell Lung Cancer (NSCLC): Used for patients who have advanced lung cancer with the EGFR T790M mutation, especially if their cancer stopped responding to older targeted drugs.
• Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Studied in men whose prostate cancer has spread and no longer responds to hormone therapy.
• B-Cell Lymphomas: Researched for certain blood cancers because of its ability to block the BTK protein.

Non-Oncological Uses (Investigational)

• Severe COVID-19 and ARDS: Used in hospitalized patients with severe lung swelling (Acute Respiratory Distress Syndrome) to stop the immune system’s dangerous “cytokine storm.”

Dosage and Administration Protocols

Because it is an oral pill, abivertinib is taken by the patient at home or in the hospital without the need for needles or IV bags.

Clinical Efficacy and Research Results

Recent clinical trial data (spanning from 2022 to 2025) shows that abivertinib is highly effective, especially for patients who have run out of other treatment options.

• Lung Cancer Survival: In long-term Phase 2 trial results for patients with EGFR T790M-mutated Non-Small Cell Lung Cancer, abivertinib showed an Overall Response Rate (ORR) of over 56%. This means the tumors shrank significantly in more than half of the patients. The median Overall Survival (OS) was an impressive 24.9 to 28.2 months for heavily pre-treated patients, with the disease stopped from growing (Progression-Free Survival) for an average of 7.5 months.
• Prostate Cancer: In the ongoing MAVERICK Phase 2 trial, combining abivertinib with standard prostate cancer medicines is showing promise in delaying the time it takes for the cancer to spread to the bones.
• Severe Infections: In Phase 2 trials for hospitalized patients with severe COVID-19 needing oxygen, those taking abivertinib showed a 20% to 25% better improvement rate and were discharged from the hospital an average of two days sooner than those who did not take the drug.

Safety Profile and Side Effects

Like all targeted therapies, abivertinib can cause side effects, though it is generally better tolerated than traditional chemotherapy.

Common Side Effects (>10%)

• Diarrhea: The most frequently reported side effect.
• Elevated Liver Enzymes (ALT/AST): Blood tests often show that the liver is working extra hard to process the medicine.
• Fatigue: Feeling very tired or weak.
• Mild Skin Rash: A minor, acne-like rash on the face or chest.

Serious Adverse Events

• Interstitial Lung Disease (ILD) / Pneumonitis: A rare but very serious swelling and scarring of the lungs (affecting about 4% of patients). It can make breathing very difficult.
• Neutropenia: A severe drop in white blood cells, which increases the risk of getting sick from an infection.

Note: As an investigational drug, abivertinib does not have a formal FDA “Black Box Warning” yet. However, doctors carefully monitor for lung inflammation, which is a known risk for all drugs in the TKI class.

Management Strategies

• For Diarrhea: Patients are usually told to drink plenty of water and use over-the-counter anti-diarrhea medicine (like loperamide) as soon as symptoms start.
• For Liver Stress: Doctors will run blood tests every few weeks. If liver enzymes get too high, the doctor will temporarily stop the pill until the liver heals.
• For Breathing Issues: If a patient suddenly gets a new cough or has trouble breathing, they must go to the emergency room immediately to check for Interstitial Lung Disease.

Research Areas

Currently, there is no major research combining abivertinib directly with stem cell transplants or regenerative medicine. Instead, modern research focuses heavily on its unique ability to block the BTK pathway. Scientists are studying how this Targeted Therapy can alter the “tumor microenvironment”—the area of cells and immune system signals surrounding a tumor. By blocking BTK, researchers hope abivertinib can “unmask” hiding cancer cells, making them more visible to the body’s natural immune defenses or to other advanced immunotherapy drugs.

Patient Management and Practical Recommendations

Taking an oral targeted therapy requires responsibility and close communication with your cancer care team.

Pre-Treatment Tests to be Performed

• Genetic Tumor Testing: A biopsy must be tested to prove the cancer has the specific EGFR T790M mutation (for lung cancer patients).
• Comprehensive Metabolic Panel (CMP): A blood test to make sure the liver and kidneys are healthy before starting.
• Complete Blood Count (CBC): To ensure the patient has enough white blood cells to fight off infections safely.

Precautions During Treatment

• Patients will need frequent blood tests, especially during the first two months of treatment, to monitor liver health.
• Because the medicine affects the immune system, patients should practice excellent handwashing and avoid large crowds during cold and flu season.

“Do’s and Don’ts” List

• Do take the medication at the same time every day to keep a steady amount of medicine in your body.
• Do call your doctor right away if you develop a fever, a new cough, or sudden shortness of breath.
• Do use sunscreen, as targeted therapies can make your skin more sensitive to the sun.
• Don’t chew, break, or crush the capsules; swallow them whole.
• Don’t eat grapefruit or drink grapefruit juice, as it can dangerously change how the medicine is absorbed in your stomach.
• Don’t start any new vitamins, herbal supplements, or other prescription drugs without asking your oncologist, as they might interact with abivertinib.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Abivertinib maleate anhydrous is currently an investigational treatment and has not been fully approved by regulatory bodies like the FDA or EMA for standard medical care outside of clinical trials. Always consult with a qualified oncologist, hematologist, or healthcare professional regarding diagnosis, treatment options, and the appropriateness of clinical trials for your specific medical condition.